An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion
Primary Purpose
Neuromuscular Scoliosis
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Clevidipine
Sponsored by
About this trial
This is an interventional treatment trial for Neuromuscular Scoliosis
Eligibility Criteria
Inclusion Criteria:
- Spinal fusion for neuromuscular scoliosis.
Exclusion Criteria:
- Allergy to dihydropyridine calcium channel antagonists
- Allergy to soy or eggs
- Non-neuromuscular causes of scoliosis
- Disorders of lipid metabolism (clevidipine is in a lipid base)
Sites / Locations
- Nationwide Children's Hospital
Arms of the Study
Arm 1
Arm Type
Active Comparator
Arm Label
Clevidipine
Arm Description
Outcomes
Primary Outcome Measures
Time to Achieve Target MAP
The time between start of clevidipine infusion and patient reaching target mean arterial pressure (MAP) at 55-65 mmHg
Secondary Outcome Measures
Full Information
NCT ID
NCT01645111
First Posted
June 8, 2012
Last Updated
February 3, 2015
Sponsor
Nationwide Children's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01645111
Brief Title
An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion
Official Title
An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion
Study Type
Interventional
2. Study Status
Record Verification Date
February 2015
Overall Recruitment Status
Completed
Study Start Date
June 2012 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
December 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nationwide Children's Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The current study would prospectively evaluate the dosing requirements, efficacy and safety of clevidipine for controlled hypotension during spinal surgery in the pediatric population. As the investigators currently have projects underway which include those patients having scoliosis surgery for idiopathic scoliosis, this trial would include only those undergoing scoliosis surgery for neuromuscular disease.
Detailed Description
This would basically be an observational study without a significant change in our current practice. There would be no change in the standard and usual anesthetic care including premedication, anesthetic induction, intraoperative anesthetic management, and intraoperative monitoring. Our usual anesthetic routine includes:
Intravenous or oral premedication with midazolam
Inhalational or intravenous induction based on the preference of the patient
Facilitation of endotracheal intubation with a dose of rocuronium with placement of intraoperative monitors including an arterial cannula
Maintenance anesthesia to include desflurane titrated to maintain the bispectral index at 40-60, fentanyl 2-4 µg/kg followed by a remifentanil infusion to maintain the mean arterial pressure at 55-65 mmHg.
Tranexamic acid to limit intraoperative bleeding
As needed, agent to control blood pressure to maintain the MAP at 55-65 mmHg if remifentanil in doses up to 0.3 µg/kg/min are ineffective.
As needed, clevidipine will be started at 1 µg/kg/min and titrated up in 1 µg/kg/min every 1-2 minutes to achieve an MAP at 55-65mmHg. Vital signs including heart rate will be recorded every 1 minute until the target MAP is achieved and then at 15 minute increments after that.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuromuscular Scoliosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Clevidipine
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Clevidipine
Primary Outcome Measure Information:
Title
Time to Achieve Target MAP
Description
The time between start of clevidipine infusion and patient reaching target mean arterial pressure (MAP) at 55-65 mmHg
Time Frame
First 30 minutes of infusion
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Spinal fusion for neuromuscular scoliosis.
Exclusion Criteria:
Allergy to dihydropyridine calcium channel antagonists
Allergy to soy or eggs
Non-neuromuscular causes of scoliosis
Disorders of lipid metabolism (clevidipine is in a lipid base)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joseph Tobias, MD
Organizational Affiliation
Nationwide Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nationwide Children's Hospital
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States
12. IPD Sharing Statement
Learn more about this trial
An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion
We'll reach out to this number within 24 hrs